rais pt
follow axnx result updat revenue/
lp estim exhibit vs prior
compar consensu updat
revenue/lp estim versu prior
compar consensu rais rel
valuat base pt reiter buy
bullish outlook strengthen weve up estim market share
gain axon sacral neuromodul devic base number
factor firstli appear us launch may come earlier
anticip label discuss commenc outstand
technic question remain launch axon full bodi
mri compat label due dilig suggest second
import improv lag dramat improv replac
interv year versu year buy interstim ii
captur physician interest fecal indic patient
isol fecal incontin mix fecal/urinari symptom
also avail close addit axon
almost person us salesforc launch effect cover
vast major implant volum told believ combin
excel clinic data valu proposit patient fewer replac
year period unfett abil full-bodi mri
without fear devic explant result rapid share shift
hard press counter outdat interstim ii earli european share
shift data england netherland share last night
confer call support revis estim assum
axon overal us revenu share exhibit ex-u share
due less intens sell effort result revenu
revenu estim versu prior
thesi believ snm market could grow
estim compound-annual-growth-rate sale
come us technolog innov axon key competit
edg r-snm lifespan longer medtron
buy interstim smaller volum full-bodi mri
compat well eas use physician patient interfac
could give critic advantag market otherwis stagnant
term innov
continu pg
tr target
thesi predic axon quickli grow revenu meaning share captur
assert mount effect competit respons henc axon
speed market key rate share buy
valuat risk pt arriv appli ev/sal multipl estim
revenu month henc exhibit ev/sal multipl in-lin faster grow
smid med-tech compani median ev/sal multipl averag exhibit
sale multipl peer group provid surrog forward multipl risk
includ fda approv delay could narrow competit window promis
modern devic and/or unforeseen hurdl quickli build larg us sale
forc and/or unanticip friction marketplac
page
strh estimatesconsensusstrh vs consensu est us sn statementstrh estimatesconsensusstrh vs consensu incom expens incom estimatesconsensusstrh vs consensusmargin axon modul technolog inc
page
sn market revenu us revenu us shareoveral market revenu market axon revenu except per share dataev sale valuationaxnx revenu ev/revenu enterpris valu debt equiti share valu per axon modul technolog inc
note entellu medic multipl calcul use transact valu entellu acquir
buy entellu medic mdwd futur sale strh estim other consensu
page
companypric ofmarketrevenuerevenu cap system vascular medic hldg diabet targetenterpris valu inc
page
except per share sn revenue- ex-u sn total revenue- duct cogs- gross fit- royalti expense- sale total oper oper incom interest interest expense- total pre-tax incom tax tax incom ep forma share share ep share adjust ebitda margin incl ebitda margin excl margin analysi sale cog margin oper ebitda margin incl ebitda margin excl fit expens growth analysi yr/yr total revenu oper incom ebitda excl inc
axon develop sacral neuromodul system sn use third-lin treatment
condit urinari incontin wet dri nonobstruct urinari retent fecal
incontin compani found headquart irvin ca
believ snm market could grow estim
compound-annual-growth-rate sale come us technolog innov axon
key competit edg r-snm lifespan longer medtron
buy interstim smaller volum full-bodi mri compat well eas
use physician patient interfac could give critic advantag market
otherwis stagnant term innov thesi predic axon quickli grow
revenu meaning share captur assert mount effect
competit respons henc axon speed market key rate share
valuat risk
pt arriv appli ev/sal multipl estim revenu
month henc ev/sal multipl in-lin faster grow smid med-tech compani
median ev/sal multipl averag sale multipl
peer group provid surrog forward multipl risk includ fda approv delay
could narrow competit window promis modern devic
and/or unforeseen hurdl quickli build larg us sale forc and/or unanticip
friction marketplac
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
